- Home
- INMB vs PLUR Comparison
INMB vs PLUR Comparison
Compare INMB & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | PLUR |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 33.9M |
| IPO Year | 2018 | 2001 |
Fundamental Metrics
Financial Performance| Metric | INMB | PLUR |
|---|---|---|
| Price | $1.37 | $3.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $5.40 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 289.9K | 4.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | $50,000.00 | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 257.14 | ★ 309.82 |
| 52 Week Low | $1.09 | $2.82 |
| 52 Week High | $11.64 | $6.10 |
Technical Indicators
Market Signals| Indicator | INMB | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 47.96 |
| Support Level | $1.15 | $3.12 |
| Resistance Level | $1.48 | $3.42 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 65.67 | 21.64 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.